← Eichor
Condition: Relapsed Refractory Marginal Zone Lymphoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Relapsed Refractory Marginal Zone Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Phase 1 · 6 location(s) · LTZ Therapeutics, Inc. · NCT07121946AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Phase 1 · 1 location(s) · Stanford University · NCT06340737Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Phase 1 · 4 location(s) · Newave Pharmaceutical Inc · NCT04775745CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Phase 1 · 1 location(s) · Marcela V. Maus, M.D.,Ph.D. · NCT06026319A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Accutar Biotechnology Inc · NCT05780034A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06563505Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT06980116MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)
Phase 1/Phase 2 · 1 location(s) · Beijing Mabworks Biotech Co., Ltd. · NCT04110301Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients Wit
Phase 3 · 19 location(s) · Beijing InnoCare Pharma Tech Co., Ltd. · NCT06082102Clinical Study of OR for Second-line Treatment of Refractory MZL
Phase 4 · 3 location(s) · Lixia Sheng · NCT061342843'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Rel
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06859008A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemi
Phase 2 · 1 location(s) · Shayna Sarosiek, MD · NCT06986174Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1 · 1 location(s) · C. Babis Andreadis · NCT04545762Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
Phase 2 · 4 location(s) · University of Miami · NCT05296070Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05846750A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Len
Phase 3 · 169 location(s) · Regeneron Pharmaceuticals · NCT06149286Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Phase 1/Phase 2 · 9 location(s) · Vironexis Biotherapeutics Inc. · NCT06533579Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractor
Phase 2 · 17 location(s) · AbbVie · NCT07387471LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Phase 1 · 1 location(s) · Medical College of Wisconsin · NCT05990465CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Phase 1/Phase 2 · 1 location(s) · Medical College of Wisconsin · NCT04186520B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide
Phase 1 · 1 location(s) · Mayo Clinic · NCT06191887Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treat
Phase 2 · 1 location(s) · University of California, Davis · NCT06905509Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Phase N/A · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137643Epco, Zanu, Ritux for R/R FL or MZL
Phase 2 · 3 location(s) · Reid Merryman, MD · NCT06563596A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 · 16 location(s) · Nurix Therapeutics, Inc. · NCT04830137Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Phase 3 · 48 location(s) · The Lymphoma Academic Research Organisation · NCT06006117A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Phase 1/Phase 2 · 7 location(s) · CRISPR Therapeutics AG · NCT05643742Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refracto
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT04223765
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.